Biogen Inc
XMUN:IDP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
Biogen Inc
XMUN:IDP
|
US |
|
Alcon AG
SIX:ALC
|
CH |
|
F
|
Fluidigm Corp
F:FLB
|
US |
|
P
|
PPG Industries Inc
SWB:PPQ
|
US |
|
GFL Environmental Inc
F:36E
|
CA |
|
A
|
Abb Ltd
XBER:ABJ
|
CH |
|
T
|
Thonburi Healthcare Group PCL
SET:THG
|
TH |
|
Mitsui Chemicals Inc
TSE:4183
|
JP |
|
E
|
ESR Cayman Ltd
OTC:ESRCF
|
HK |
|
P
|
Postal Savings Bank of China Co Ltd
F:3YB
|
CN |
|
Bridgepoint Group PLC
LSE:BPT
|
UK |
|
F
|
Fresnillo PLC
F:FNL
|
MX |
|
London Stock Exchange Group PLC
F:LS4D
|
UK |
|
F
|
Fujitsu Ltd
DUS:FUJ1
|
JP |
|
V
|
Valneva SE
VSE:VLA
|
FR |
|
N
|
Nokia Oyj
XBER:NOA3
|
FI |
|
Mettler-Toledo International Inc
NYSE:MTD
|
US |
|
China Literature Ltd
OTC:CHLLY
|
CN |
|
D
|
De' Longhi SpA
SWB:DLN
|
IT |
|
R
|
Rugvista Group AB (publ)
STO:RUG
|
SE |
|
R
|
Relx PLC
XETRA:RDEB
|
UK |
|
Mondi PLC
LSE:MNDI
|
UK |
|
E
|
E ON SE
BET:EON
|
DE |
|
G
|
Grupo Empresas Navieras SA
SGO:NAVIERA
|
CL |
Biogen Inc
Biogen is a biotechnology company that develops and sells medicines for serious diseases, with a long focus on conditions that affect the brain and nervous system. Its main products are prescription drugs for diseases such as multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease, and certain rare neurological disorders. It also works on therapies for immunology and related areas, but its business is centered on specialty medicines that are prescribed by doctors rather than sold over the counter. The company makes money mainly by selling branded drugs to hospitals, clinics, pharmacies, and other healthcare providers. In some cases it also earns income from product royalties and collaborations with other drugmakers. Because these are complex medicines used in specialized care, Biogen’s business depends on scientific research, regulatory approval, and ongoing relationships with neurologists, specialists, and payers who decide whether patients can access the treatments. What makes Biogen different is that it sits at the high-science end of the pharmaceutical chain: it turns research in biology and neurology into treatments for hard-to-treat diseases. Instead of competing on broad, everyday medicines, it focuses on a smaller set of branded therapies where patient need is high and medical expertise matters. That gives Biogen a business model built around patents, clinical data, specialist prescribing, and close ties to the healthcare system.
Biogen is a biotechnology company that develops and sells medicines for serious diseases, with a long focus on conditions that affect the brain and nervous system. Its main products are prescription drugs for diseases such as multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease, and certain rare neurological disorders. It also works on therapies for immunology and related areas, but its business is centered on specialty medicines that are prescribed by doctors rather than sold over the counter.
The company makes money mainly by selling branded drugs to hospitals, clinics, pharmacies, and other healthcare providers. In some cases it also earns income from product royalties and collaborations with other drugmakers. Because these are complex medicines used in specialized care, Biogen’s business depends on scientific research, regulatory approval, and ongoing relationships with neurologists, specialists, and payers who decide whether patients can access the treatments.
What makes Biogen different is that it sits at the high-science end of the pharmaceutical chain: it turns research in biology and neurology into treatments for hard-to-treat diseases. Instead of competing on broad, everyday medicines, it focuses on a smaller set of branded therapies where patient need is high and medical expertise matters. That gives Biogen a business model built around patents, clinical data, specialist prescribing, and close ties to the healthcare system.
Strong start: Biogen said it had a very strong first quarter, with total revenue of $2.5 billion, up 2% year over year, and earnings also moving higher.
Growth products: The company’s growth products generated $851 million, up 12% year over year, and now bring in more revenue than Biogen’s remaining MS products.
LEQEMBI momentum: LEQEMBI end market revenue rose to $168 million, up 74% year over year, with continued growth in the U.S., Japan and China and a May 24 PDUFA date for subcutaneous initiation.
Pipeline catalysts: Management highlighted several 2026 and 2027 readouts, including BIIB080, litifilimab, felzartamab and zorevunersen, while saying the late-stage pipeline is getting stronger.
Apellis deal: Biogen reiterated that the planned Apellis acquisition would add two marketed medicines, be accretive in 2027, and help expand its immunology and rare disease growth profile.
SPINRAZA update: High-dose SPINRAZA has already begun to gain traction in the U.S. and Europe, with management saying it could help stabilize and grow the franchise over time.
